RxDoctor Payments Data

Mona Amirkhani

Laguna Niguel, CANPI 1831785237

Payments from drug & device makers

$2,901in general payments, 2019–2025

Across 127 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$396
  • AstraZeneca$343
  • Novo Nordisk$195
  • Bayer$181
  • Amgen$161
  • plus $537 from 14 others

What the payments were for

  • Food & beverage$2,901100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl39$3,269
Temazepam12$697
Alprazolam136$472
Pregabalin11$282
Zolpidem Tartrate36$281
Levothyroxine Sodium18$259
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$255
Atorvastatin Calcium16$137
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$134
Lorazepam21$80
Azithromycin11$37

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →